ENTA

Enanta Pharmaceuticals, Inc. Press Releases

$39.0867
*  
0.3767
0.97%
Get ENTA Alerts
*Delayed - data as of Jul. 23, 2014 14:51 ET  -  Find a broker to begin trading ENTA now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    ENTA Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Enanta Pharmaceuticals Announces European Medicines Agency Validates Marketing Authorization Applications for AbbVie’s Investigational, All-Oral, Interferon-Free Regimen for Genotype 1 Chronic Hepatitis C
6/17/2014 2:03:00 AM - Business Wire

European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C
6/17/2014 2:00:00 AM - PR Newswire

Enanta Pharmaceuticals Announces U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Regimen for Genotype 1 Chronic Hepatitis C
6/13/2014 3:39:00 PM - Business Wire

U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C
6/13/2014 3:34:00 PM - PR Newswire

Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
6/10/2014 4:05:00 PM - Business Wire

Enanta Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference
5/22/2014 8:30:00 AM - Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2014
5/12/2014 7:30:00 AM - Business Wire

Enanta Pharmaceuticals Announces the Appointment of Nathaniel S. Gardiner, J.D. as Senior Vice President and General Counsel
5/12/2014 7:15:00 AM - Business Wire

Enanta Pharmaceuticals Announces Submission of EU Marketing Authorization Applications to the European Medicines Agency for All-Oral, Interferon-Free Hepatitis C Regimen Containing ABT-450
5/8/2014 2:03:00 AM - Business Wire

AbbVie Submits for EU Marketing Authorization its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Chronic Hepatitis C
5/8/2014 2:00:00 AM - PR Newswire

Enanta Pharmaceuticals to Present at the 39th Annual Deutsche Bank Securities Healthcare Conference
4/30/2014 8:30:00 AM - Business Wire

Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Second Quarter and Six Months Ended March 31, 2014
4/28/2014 8:30:00 AM - Business Wire